164 related articles for article (PubMed ID: 35210509)
21. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Ferrari A; Spina M; Tucci A; Stelitano C; Capodanno I; Fragasso A; Baldini L; Bottelli C; Montechiarello E; Fogazzi S; Lamorgese C; Cavalli L; Federico M;
Leuk Lymphoma; 2014 Jan; 55(1):38-43. PubMed ID: 23517562
[TBL] [Abstract][Full Text] [Related]
22. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
23. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
[TBL] [Abstract][Full Text] [Related]
24. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T; Yoshikawa T; Goto H; Sawada M; Yamada T; Fukuno K; Kasahara S; Shibata Y; Matsumoto T; Mabuchi R; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Nannya Y; Katsumura N; Takahashi T; Kito Y; Takami T; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2018 Oct; 36(4):638-644. PubMed ID: 29882279
[TBL] [Abstract][Full Text] [Related]
25. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F
Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
Park S; Hong J; Hwang I; Ahn JY; Cho EY; Park J; Cho EK; Shin DB; Lee JH
J Geriatr Oncol; 2015 Nov; 6(6):470-8. PubMed ID: 26522808
[TBL] [Abstract][Full Text] [Related]
27. Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment - A systematic review.
Tavares A; Moreira I
Crit Rev Oncol Hematol; 2021 Apr; 160():103294. PubMed ID: 33675907
[TBL] [Abstract][Full Text] [Related]
28. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
29. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Laribi K; Denizon N; Bolle D; Truong C; Besançon A; Sandrini J; Anghel A; Farhi J; Ghnaya H; Baugier de Materre A
Ann Hematol; 2016 Oct; 95(10):1705-14. PubMed ID: 27485454
[TBL] [Abstract][Full Text] [Related]
30. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma.
Kobayashi Y; Miura K; Hojo A; Hatta Y; Tanaka T; Kurita D; Iriyama N; Kobayashi S; Takeuchi J
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1079-84. PubMed ID: 21221637
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive geriatric assessment predicts mortality and adverse outcomes in hospitalized older adults.
Avelino-Silva TJ; Farfel JM; Curiati JA; Amaral JR; Campora F; Jacob-Filho W
BMC Geriatr; 2014 Dec; 14():129. PubMed ID: 25464932
[TBL] [Abstract][Full Text] [Related]
32. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
33. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
34. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Castellucci P; Marchi E; Farsad M; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Bacci F; Pileri S; Baccarani M
Ann Oncol; 2008 Apr; 19(4):769-73. PubMed ID: 18303033
[TBL] [Abstract][Full Text] [Related]
36. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
37. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
38. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the
Storti S; Spina M; Pesce EA; Salvi F; Merli M; Ruffini A; Cabras G; Chiappella A; Angelucci E; Fabbri A; Liberati AM; Tani M; Musuraca G; Molinari A; Petrilli MP; Palladino C; Ciancia R; Ferrario A; Gasbarrino C; Monaco F; Fraticelli V; De Vellis A; Merli F; Luminari S
Haematologica; 2018 Aug; 103(8):1345-1350. PubMed ID: 29748444
[TBL] [Abstract][Full Text] [Related]
39. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
40. Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.
Millar A; Ellis M; Mollee P; Cochrane T; Fletcher J; Caudron A; Webster B; Trotman J
Intern Med J; 2015 Nov; 45(11):1147-53. PubMed ID: 26337606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
